World news and discussion on TalkFuse.
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences, the de-extinction startup known for its dire wolf "resurrection" project, is reportedly in talks to raise new funding at a valuation of $20 billion to $30 billion, according to Axios. This would roughly double or triple the $10.2 billion valuation it held around 16 months ago, reflecting growing investor appetite for the company despite ongoing debate over the scientific and ethical merits of de-extinction work.
It is not yet known who would lead the round or how much capital the five-year-old company is seeking, but it has reportedly begun generating revenue over the past year. Colossal's chief executive Ben Lamm has pointed to three revenue streams, including conservation technology sold to the US government and the UAE, which recently invested $60 million. The company has also spun out three ventures — plastics-recycling firm Breaking, computational biology platform Form Bio, and AI modelling company Astromech, valued at $2 billion in March — and plans to spin off its artificial womb technology, expected to be ready next year, alongside potential future revenue from biodiversity credits.
In short
- Colossal Biosciences in talks for a $20bn–$30bn valuation
- Up sharply from $10.2bn about 16 months ago
- Firm now earning revenue via conservation tech and spinout companies
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
This valuation reflects rational recognition of Colossal's substantive technological achievements and diversified commercial potential. The company has already generated revenue from conservation technology sold to governments and the UAE, demonstrating genuine market demand. Its portfolio—including plastics recycling, computational biology, AI modelling, and forthcoming artificial womb technology—represents real intellectual property with commercial applications. Emerging markets like biodiversity credits align with increasing environmental regulation and corporate sustainability commitments, suggesting sustainable demand separate from de-extinction's speculative nature.
The case against
The valuation appears inflated relative to demonstrated financial performance and scientific certainty. De-extinction remains unproven and ethically contested, yet dominates the company's public profile and investor narrative. Whilst individual ventures show promise, they lack the proven track records justifying a $20–30 billion valuation. Revenue claims remain modest relative to the valuation multiple. This represents venture capital chasing trendy biotech concepts rather than rigorous analysis of profitability and scalability—a pattern historically preceding investment corrections.
Explained simply
Colossal Biosciences is a five-year-old startup working on de-extinction, the technology of resurrecting extinct animal species. The company is best known for its project to recreate the dire wolf, a large predator that went extinct thousands of years ago.
De-extinction remains a debated field among scientists and ethicists, with experts divided on both its scientific feasibility and moral implications. The debate includes technical questions about whether such resurrection is possible, as well as ethical questions about whether it should be pursued.
Colossal has attracted investor interest through a business model that extends beyond its core de-extinction work. The company generates revenue from conservation technology sold to governments and other entities, and has spun off separate ventures in plastics recycling and artificial intelligence as independent businesses.
Americas Art Business Celebrity Companies Cricket Culture Entertainment Sport World